105 POSTER A prospective study of the cutaneous side effects of sorafenib, a novel multi-kinase inhibitor

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

“…Although this multikinase inhibitor has an excellent safety profile, more than 90% of patients experience skin reactions after receiving this agent, including hand‐foot skin reaction in 60% of patients 3,4 . The aetiology of this unique skin condition is yet to be determined, although symptoms can be managed with topical treatment or dose reduction or discontinuation of sorafenib therapy 4,5 . This study reports the clinical and histopathological findings of hand‐foot skin reaction produced by this multikinase inhibitor.…”

“…The drug is currently approved for the treatment of advanced renal cell cancer 2,3 . Although this multikinase inhibitor has an excellent safety profile, more than 90% of patients experience skin reactions after receiving this agent, including hand‐foot skin reaction in 60% of patients 3,4 . The aetiology of this unique skin condition is yet to be determined, although symptoms can be managed with topical treatment or dose reduction or discontinuation of sorafenib therapy 4,5 .…”